News

Piper Sandler Adjusts HBT Financial Price Target Insights

Piper Sandler Adjusts HBT Financial Price Target Insights

Piper Sandler Adjusts Price Target for HBT Financial

Piper Sandler has recently made an adjustment to its price target for shares of HBT Financial (NASDAQ: HBT), lowering it from $25 to $24. This change comes alongside maintaining a Neutral rating on the stock, highlighting a careful outlook in light of the company's recent performance.

Third-Quarter Results Reflect Growth

The adjustment follows a detailed examination of HBT Financial's third-quarter results, which indicated a significant boost in revenue. This growth was largely driven by an unexpected rise in the Net Interest Margin (NIM) and an increase in core fee income. Analysts have maintained a positive outlook on HBT's credit quality, noting it as a stable aspect that is expected to remain robust.

Challenges in the Current Environment

Despite the encouraging data, the analyst notes that the current interest rate environment poses short-term challenges. There may be impacts on net interest income (NII) and NIM over the near to intermediate term that investors should keep an eye on.

Long-term Potential for Defensive Investment

Despite these potential headwinds, Piper Sandler views HBT Financial as an appealing long-term investment. The bank's strong profitability profile, combined with its credit quality, provides a sense of security even across various economic fluctuations. Furthermore, the bank’s growing reserve of excess capital offers promising prospects for future mergers and acquisitions, which could significantly enhance earnings per share (EPS).

Updated Earnings Estimates

Looking ahead, the analysts at Piper Sandler have increased their fourth-quarter 2024 earnings estimate to $0.58 per share, marking a rise of $0.02 based on expectations of higher core fee income. However, the 2025 earnings per share estimate remains steady at $2.10. Additionally, for 2026, a new earnings estimate of $2.15 has been introduced, showcasing ongoing confidence in HBT Financial’s growth trajectory.

Market Reactions and Analyst Upgrades

HBT Financial is receiving considerable attention from analysts currently. Several firms have upgraded their ratings, with BofA assigning a Buy rating to SLM Corp and praising its potential for capital returns. In parallel, HBT Financial has announced a quarterly cash dividend of $0.19 per share, reinforcing its commitment to delivering returns to shareholders.

Positive Adjustments Following Strong Performances

The recent financial performance of HBT Financial has garnered recognition from various analysts including Piper Sandler, Raymond James, and Keefe, Bruyette & Woods. These firms have raised their price targets, a clear indication of the bank's robust second-quarter performance and its ability to mitigate potential NIM compression moving forward.

Strategic Outlook and Prospective Growth

DA Davidson has also reviewed its outlook on HBT Financial, increasing the price target to $26 from a previous $22. They attribute this upward revision to the company's impressive second-quarter results and highlighted HBT Financial’s proactive strategies concerning mergers, acquisitions, and effective expense management.

Recent Analyst Ratings and Market Insights

In noteworthy developments, Keefe, Bruyette & Woods have also raised their target for HBT Financial stock while affirming an Outperform rating. This decision came after HBT’s earnings report, illustrating a performance that slightly surpassed market expectations.

InvestingPro Insights

Additional insights from recent data suggest that the P/E ratio of HBT Financial is at 10.36, positioning it as a value-oriented stock with substantial near-term earnings growth potential. The PEG ratio of 0.79 further supports the notion that shares may be undervalued against expected growth. Investors looking for income should take note of HBT’s dividend yield of 3.54%, along with a significant dividend growth of 11.76% over the past twelve months.

Prospects for Profitability Amidst Challenges

While HBT is likely to remain profitable this year, the company does confront challenges related to weak gross profit margins. This perspective echoes Piper Sandler’s cautious outlook alongside the revised price target. Investors are encouraged to look closely at HBT Financial’s performance as it navigates these complexities.

Frequently Asked Questions

What prompted Piper Sandler to adjust the price target for HBT Financial?

The adjustment stemmed from recent earnings reports that indicated both strong revenue and challenges presented by the current interest rate environment.

What are the new earnings estimates for HBT Financial?

Piper Sandler has increased the fourth-quarter 2024 estimate to $0.58, while maintaining the 2025 estimate at $2.10 and introducing a 2026 estimate of $2.15.

How has HBT Financial performed recently according to analysts?

Analysts have noted strong second-quarter performance, leading to multiple upgrades and positive adjustments of price targets for HBT Financial.

Is HBT Financial considered a good long-term investment?

Yes, Piper Sandler views HBT Financial as a strong long-term investment due to its solid profitability and credit quality.

What is HBT Financial's current dividend yield?

The dividend yield for HBT Financial stands at 3.54%, with notable growth over the past year, making it attractive to income-focused investors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 71

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 92

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
STVN's GLP-1 Fumble Sparks Shareholder Scrutiny

Updated Category News Views 35

The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading
ROBOTWORLD 2026: AI Reshapes Industrial Horizons

Updated Category News Views 48

A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 94

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 0

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 101

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Compass Faces Securities Fraud Suit: Deadline Looms

Updated Category News Views 45

Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...

Continue Reading
s of Cautious Optimism - Continue Reading" aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism"> Continue Reading